Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: Evaluation of cardiovascular events in a randomized trial

Scandinavian Journal of Urology and Nephrology

Volumn 45, Issue 5, 2011, Pages 346-353

  Hedlund, Per Olov ^a   Johansson, Robert ^b   Damber, Jan Erik ^c   Hagerman, Inger ^a   Henriksson, Peter ^d   Iversen, Peter ^e   Klarskov, Peter ^f   Mogensen, Peter ^g   Rasmussen, Finn ^f   Varenhorst, Eberhard ^h  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d DANDERYD HOSPITAL   (Sweden)

^e University of Copenhagen   (Denmark)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^g FREDERIKSBERG HOSPITAL   (Denmark)

^h LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

cardiovascular events; cardiovascular risk factors; combined androgen deprivation; parenteral oestrogen therapy; prostate cancer; randomized multicentre trial; skeletal metastases

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANDROGEN; FLUTAMIDE; POLYESTRADIOL PHOSPHATE; TRIPTORELIN; WARFARIN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BRAIN ISCHEMIA; CANCER STAGING; CARDIOLOGIST; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG MEGADOSE; HEART FAILURE; HUMAN; INTERMITTENT CLAUDICATION; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; VEIN THROMBOSIS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; ESTRADIOL; ESTROGENS; FLUTAMIDE; HUMANS; INFUSIONS, PARENTERAL; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; TRIPTORELIN PAMOATE;

EID: 80054055688     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.585820     Document Type: Article

References (13)

1. Henriksson P, Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral estrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65:282-5.
2. Henriksson P, Carlström K, Pousette Å, Gunnarsson PO, Johansson CJ, Eriksson B, et al. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics and endocrine and clinical effects of a parenteral estrogen regimen. Prostate 1999;40:76-82. (Pubitemid 29304697)
3. Henriksson P, Eriksson A, Stege R, Collste L, Pousette Å, von Schoultz B, et al. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate. Prostate 1988;13:257-61. (Pubitemid 19037033)
4. Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) study no 5. Scand J Urol Nephrol 2008;442:220-9. (Pubitemid 351574386)
5. Hedlund PO, Gustafson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. Scand J Urol Nephrol Suppl 1980;55:103-5.
6. Mikkola A, Aro J, Rannikko S, Ruutu M, on behalf of the Finnprostate Group. A high pretreatment plasma oestradiol level is associated with low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer. Br J Urol Int 2008;101:1090-5. (Pubitemid 351502649)
7. Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer. Scandinavian Prostatic Cancer Group study no 5. Scand J Urol Nephrol 2002;36:405-13. (Pubitemid 36169498)
8. Soloway MS. The importance of prognostic factors in advanced prostate cancer. Cancer 1990;66:1017-21. (Pubitemid 20292998)
9. Eisen M, Napp HE, Vock R. Inhibition of platelet aggregation caused by estrogen treatment in patients with carcinoma of the prostate. J Urol 1975;114:93-7.
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56. (Pubitemid 46630983)
11. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelsson A. Absolute and relative risk of cardiovascular disease in men with prostate cancer: Results from the population-based PCBaSe Sweden. J Clin Oncol 2010; 28:3448-56.
12. Blombäck M, Hedlund PO, Säwe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimes for prostate cancer - predictors for cardiovascular complications? Thromb Res 1988;49: 111-21. (Pubitemid 18037063)
13. Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E. Scandinavian Prostate Cancer Group-5 trial study. Prospective evaluation of hot flashes during treatment with parenteral oestrogen or complete androgen ablation for metastatic carcinoma of the prostate. J Urol 2001;166: 517-20. (Pubitemid 32652235)